PhaseBio Pharmaceuticals Inc: insider trades · United States · SEC (Form 4)

About PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals Inc. is a U.S.-based biopharmaceutical company historically focused on developing therapies for cardiovascular and cardiopulmonary diseases. Its principal executive offices were in Malvern, Pennsylvania, with an additional operational presence in San Diego, California. The company was founded as a clinical-stage biotech business with a mission to address serious diseases where treatment options remained limited. From a market perspective, PhaseBio was associated with the NASDAQ market in the United States before its share listing was suspended in the context of financial distress and the Chapter 11 process the company initiated in October 2022. PhaseBio’s core scientific asset was its proprietary elastin-like polypeptide, or ELP, platform. The platform was designed to improve the pharmacokinetics of proteins and peptides by extending half-life and supporting less frequent dosing. This technology underpinned the company’s research strategy and gave it a differentiated angle versus more conventional biotech approaches. The best-known program in its pipeline was bentracimab, also known as PB2452, a reversal agent intended to rapidly and sustainably neutralize the antiplatelet effects of ticagrelor in patients experiencing major bleeding or requiring urgent surgery or invasive procedures. For a long time, bentracimab represented the company’s lead value driver and the program most closely watched by investors. In competitive terms, PhaseBio operated in a narrow, high-need specialty area at the intersection of cardiology, acute care, and hemostasis. Its key competitive rationale was the potential lack of a like-for-like alternative for ticagrelor reversal, which made the asset clinically important for hospitals, emergency physicians, and procedural teams. The company also pursued external value creation through partnerships, including a licensing agreement with Alfasigma for commercialization rights in certain non-U.S. markets, highlighting an attempt to monetize the asset beyond its own commercial infrastructure. Geographically, PhaseBio was primarily U.S.-centered, with research, management, and corporate functions based in the United States, while its commercialization strategy relied in part on international partners. Recent milestones that matter to investors include the Chapter 11 filing in October 2022, the loss of ongoing NASDAQ listing continuity, and subsequent disclosures tied to the restructuring and transfer of assets. For equity analysts, PhaseBio should therefore be viewed as a highly specialized clinical-stage biotechnology company whose investment case depended largely on a small number of programs and on the outcome of restructuring and asset disposition events in the United States.